The nondystrophic myotonias

被引:0
|
作者
Chad R. Heatwole
Richard T. Moxley
机构
[1] University of Rochester,Department of Neurology
[2] University of Rochester,Department of Pediatrics
来源
Neurotherapeutics | 2007年 / 4卷
关键词
Nondystrophic myotonia; Becker’s disease; Thomsen’s disease; myotonia levior; paramyotonia congenita; hyperkalemic periodic paralysis with myotonia;
D O I
暂无
中图分类号
学科分类号
摘要
The nondystrophic myotonias are a heterogeneous set of rare diseases that demonstrate clinical myotonia, electrical myotonia, or both. These disorders are distinguished from myotonic dystrophy type 1 (DM-1), the more recently described proximal myotonic myopathy/myotonic dystrophy type 2 (PROMM/DM-2), and proximal myotonic dystrophy (a variant of DM-2) by characteristic clinical features, lack of abnormal nucleotide repeat expansions in the DM-1 and DM-2 genes, lack of cataracts and endocrine disturbances, and absence of significant histopathology in the muscle biopsy. The present article reviews each of the nondystrophic myotonias by exploring the unique clinical features, electrodiagnostic findings, diagnostic criteria, gene mutations, and response to pharmacologic therapy. These diseases are divided into those with chloride channel dysfunction (the myotonia congenita disorders) and those with sodium channel dysfunction (paramyotonia congenita, potassium-aggravated myotonia, and hyperkalemic periodic paralysis with myotonia). The variants that occur in each of these conditions are commented on. The differentiating features of the nondystrophic myotonias are summarized, and their predominant clinical, electrodiagnostic, and genetic characteristics are tabulated. For a comprehensive review of pertinent research and studies with application to diagnosis and treatment of individuals with nondystrophic myotonic disorders, the present article is best read in the context of other articles in this issue, especially those on ion channel physiology (Cannon) and pharmacology (Conte-Camerino), and on hyperkalemic periodic paralysis (Lehmann-Horn).
引用
收藏
页码:238 / 251
页数:13
相关论文
共 50 条
  • [41] Nondystrophic holocord intramedullary lipoma: an uncommon case
    Bansal, Sumit
    Sahu, Rabi Narayan
    Patnaik, Ashis
    [J]. CHILDS NERVOUS SYSTEM, 2018, 34 (04) : 591 - 592
  • [42] Myotonias and army personnel:: Symptoms and effects on service fitness
    Mäkelä, JP
    Somer, H
    [J]. MILITARY MEDICINE, 2005, 170 (09) : 806 - 809
  • [43] NONPROGRESSIVE MYOTONIAS - CLINICAL AND GENETIC-ASPECTS
    KOCH, M
    HARPER, PS
    [J]. JOURNAL OF MEDICAL GENETICS, 1987, 24 (10) : 634 - 634
  • [44] Periodic palsies and myotonias are ion channel diseases
    Fontaine, B
    Fardeau, M
    [J]. REVUE NEUROLOGIQUE, 1996, 152 (10) : 579 - 586
  • [45] CLINICOPHYSIOLOGICAL AND HISTOCHEMICAL CRITERIA IN THE ASSESSMENT OF THE EFFICACY OF PHYSIOTHERAPY OF MYOTONIAS
    LOBZIN, VS
    SAIKOVA, LA
    SHIMAN, AG
    PUSTOZEROV, VG
    [J]. ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 1990, 90 (03): : 35 - &
  • [46] Magnetic resonance imaging in the non-dystrophic myotonias
    Morrow, J. M.
    Matthews, E.
    Rayan, D. L. Raja
    Amer, I.
    Fischmann, A.
    Sinclair, C. D. J.
    Thornton, J. S.
    Reilly, M. M.
    Yousry, T. A.
    Hanna, M. G.
    [J]. NEUROMUSCULAR DISORDERS, 2011, 21 : S5 - S5
  • [48] The roles of mitochondrial tRNA mutations in non-dystrophic myotonias
    Yu, Xue-Jiao
    Ding, Yu
    [J]. MITOCHONDRIAL DNA PART B-RESOURCES, 2020, 5 (03): : 3796 - 3801
  • [49] Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia
    van den Berg, Sibren
    van der Wel, Vincent
    de Visser, Saco J.
    Stunnenberg, Bas C.
    Timmers, Lonneke
    van der Ree, Martijn H.
    Postema, Pieter G.
    Hollak, Carla E. M.
    [J]. VALUE IN HEALTH, 2021, 24 (07) : 925 - 929
  • [50] In vivo assessment of muscle membrane properties in the sodium channel myotonias
    Tan, S. Veronica
    Z'Graggen, Werner J.
    Hanna, Michael G.
    Bostock, Hugh
    [J]. MUSCLE & NERVE, 2018, 57 (04) : 586 - 594